NCT04408638
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- NCT04408638 ↗
- Active, not recruiting
- Hoffmann-La Roche
- Deep
We haven't built an HCP commentary report on NCT04408638 (obinutuzumab, glofitamab and 4 more in Diffuse Large B-cell Lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
HCP commentary on NCT04408638 so far
What clinicians have said in podcasts, YouTube videos and X posts we have indexed. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 76 | |
| YouTube | 73 | |
| Podcasts | 40 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Glofitamab in Combination With Gemcitabine Plus Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- Obinutuzumab; Glofitamab; Rituxumab; Tocilizumab; Gemcitabine; Oxaliplatin
- Arms
- Glofit-GemOx · Experimental
- R-GemOx · Experimental
- Enrollment
- 270 (estimated)
- Primary outcomes
- Overall survival (OS), defined as the time from randomization to date of death from any cause
- Sponsor
- Hoffmann-La Roche
- Start
- Feb 23, 2021
- Primary completion
- Mar 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT04408638 · updated Oct 2, 2026
Publications
linked from the registry- Abramson JS, Townsend W, Fox CP, Ku M, Hertzberg M, Huang HQ, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Mulvihill E, Kesavan M, Kallemeijn M, Ta R, Choeurng V, Belousov A, Relf J, Bottos A, Lundberg L, Gregory GP. Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO. Blood Adv. 2026 Aug 11;10(15):5367-5377. doi: 10.1182/bloodadvances.2026019764. PubMed 42269085
- Sam J, Leclercq-Cohen G, Gebhardt S, Surowka M, Herter S, Lechner K, Relf J, Briner S, Varol A, Appelt B, Domocos I, Nicolini V, Bez M, Bommer E, Jenni S, Schoenle A, Le Clech M, Colombetti S, Klein C, Umana P, Lundberg P, Korfi K, Bottos A, Bacac M. Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma. Blood. 2025 Oct 9;146(15):1824-1836. doi: 10.1182/blood.2025028863. PubMed 40749164
- Abramson JS, Ku M, Hertzberg M, Huang HQ, Fox CP, Zhang H, Yoon DH, Kim WS, Abdulhaq H, Townsend W, Herbaux C, Zaucha JM, Zhang QY, Chang H, Liu Y, Cheah CY, Ghesquieres H, Simko S, Orellana-Noia V, Ta R, Relf J, Dixon M, Kallemeijn M, Mulvihill E, Huang H, Lundberg L, Gregory GP. Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial. Lancet. 2024 Nov 16;404(10466):1940-1954. doi: 10.1016/S0140-6736(24)01774-4. PubMed 39550172